COX-2 inhibitors

Lancet

Volumn 353, Issue 9149, 1999, Pages 307-314

  Hawkey, C J ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 BROMO 2 (4 FLUOROPHENYL) 3 (4 METHYLSULFONYLPHENYL)THIOPHENE; ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETODOLAC; FLURBIPROFEN; IBUPROFEN; MELOXICAM; NABUMETONE; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; ROFECOXIB; UNCLASSIFIED DRUG;

ANALGESIA; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG EFFECT; DRUG ELIMINATION; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME INHIBITION; GASTROINTESTINAL TOXICITY; HUMAN; NONHUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; THROMBOSIS;

EID: 0033031331     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)12154-2     Document Type: Review

References (75)

1. Fu JY, Masferrer JL, Seibert K, Raz A, Needlemann P The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem. 265:1990;16737-16740.
2. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem. 266:1991;12866-12872.
3. Picot D, Loll PJ, Garavito RM The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature. 367:1994;243-249.
4. Luong C, Miller A, Barnett J, Chow J, Ramasha C, Browner MF The structure of human cyclooxygenase-2; conservation and flexibility of the NSAID binding site. Nat Struct Biol. 3:1996;927-933.
5. Lanzo CA, Beechem JM, Talley J, Marnett LJ Investigation of the binding of isoform-selective inhibitors to prostaglandin endoperoxide synthases using fluorescence spectroscopy. Biochemistry. 37:1998;217-226.
6. Gierse J, McDonald J, Hauser S, Rangwala S, Seibert K A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors. J Biol Chem. 271:1996;15810-15814.
7. Ford-Hutchinson AW. New highly selective COX-2 inhibitors. In: Vane J, Botting J, eds. Selective COX-2 inhibitors: pharmacology, clinical effects and therapeutic potential. London: William Harvey Press, 1997: 117-25.
8. Gans KR, Galbraith W, Roman RJet al. Anti-inflammatory and safety profile of DuP697, a novel orally effective prostaglandin synthesis inhibiton. J Pharmacol Exp Ther. 254:1990;180-207.
9. Pairet M, Van Ryn J, Mauz A, et al. Differential inhibition of COX-1 and COX-2 by NSAIDs: a summary of results obtained using various test systems. In: Vane J, Botting J, eds. Selective COX-2 inhibitors: pharmacology, clinical effects and therapeutic potential. Dordrecht: Kluwer Academic Publishers, 1997; 3: 27-46.
10. Jackson LM, Wu K, Mahida YRet al. COX-1 expression in human gastric mucosa infected with Helicobacter pylori: constitutive or induced? Gastroenterology. 114:1998;A160.
11. Noble S, Balfour JA Meloxicam. Drugs. 51:1996;424-432.
12. Patrignani P, Panara MR, Sciulli MG, Santini G, Renda G, Patrono C Differential inhibition of human prostaglandin endoperoxide synthase-1 and -2 by nonsteroidal anti-inflammatory drugs. J Physiol Pharmacol. 48:1997;623-631.
13. Goeithe HS, Lund B, Distel MR, Bluhmki E A double-blind, randomized trial to compare meloxicam 15 mg with diclofenac 100 mg in the treatment of osteoarthritis of the knee. Osteoarthritis Cartilage. 15:1997;283-288.
14. Linden B, Distel M, Bluhmki E. A double-blind study to compare the efficacy and safety of meloxicam 15 mg with piroxicam 20 mg in patients with osteoarthritis of the hip. Br J Rheumatol 1996; 35 (suppl 1): 35-38.
15. Hosie J, Distel M, Bluhmki E. Meloxicam in osteoarthritis: a six months, double-blind comparison with diclofenac sodium. Br J Rheumatol 1996; 35 (suppl 1): 39-43.
16. Hosie J, Distel M, Bluhmki E Efficacy and tolerability of meloxicam versus piroxicam in patients with osteoarthritis of the hip or knee: a six-month double-blind study. Clin Drug Invest. 13:1997;175-184.
17. Wojtulewski JA, Schattenkirchner M, Barcelo P, et al. A six months double-blind trial to compare the efficacy and safety of meloxicam 7·5 mg daily and naproxen 750 mg daily in patients with rheumatoid arthritis. Br J Rheumatol 1996; 35 (suppl 1): 22-28.
18. Patoia I, Santucci I, Furno Pet al. A four-week, double-blind, parallel-group study to compare the gastrointestinal effects of meloxicam 7·5 mg, meloxicam 15 mg, piroxicam 20 mg and placebo by means of faecal blood loss, endoxcopy and symptoms evaluation in healthy volunteer. Br J Rheumatol. 35:1996;61-67.
19. Distel M, Mueller C, Bluhmki E, et al. Global analysis of safety of a new NSAID, meloxicam. Br J Rheumatol 1996; 35 (suppl 1): 68-77.
20. Hawkey C, Kahan A, Steinbruck Ket al. Gastrointestinal tolerabability of the COX-2 inhibitor, meloxicam, in osteoarthritis patients: the meloxicam large scale internatinal study safety assessment (MELISSA). Br J Rheumatol. 37:1998;937-945.
21. Dequeker J, Hawkey C, Kahan Aet al. Improvement in gastrointestinal tolerabilityof the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the safety and efficacy large-scale evaluation of COX-inhibiting therapies (SELECT) trial in osteoarthritis. Br J Rheumatol. 37:1998;946-951.
22. Davis R, Brogden RN Nimesulide: an update on its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs. 48:1994;431-454.
23. Tavares IA, Bishai PM, Bennett A Activity of nimesulide on constitutive and inducible cyclooxygenases. Arzneimittelforschung. 45:1995;1093-1095.
24. Garcia Rodriguez LA, Cattaruzzi C, Troncon MG, Agostinis L Risk of hospitalisation for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch Intern Med. 158:1998;33-39.
25. Glaser K, Sung ML, O'Neill Ket al. Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1. Eur J Pharmacol. 281:1995;107-111.
26. Hallyar J, Bjarnason I NSAIDs, COX-2 inhibitors, and the gut. Lancet. 346:1995;521-522.
27. Cipollone F, Ganci A, Panara MR, Greco A, Cuccurullo F, Patrono C Effects of nabumetone on prostanoid synthesis in humans. Clin Pharmacol Ther. 58:1995;335-341.
28. Brooks P, Emery P, Evans J, et al Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2. Br J Rheumatol (in press).
29. Penning TD, Talley JJ, Bertenshaw SRet al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-y]benzenesulfonamide (SC-58635, celecoxib). J Med Chem. 40:1997;1347-1365.
30. Isakson P, Zweifel B, Masferrer J, et al. Specific COX-2 inhibitors: from bench to bedside. In: Vane J, Botting J, eds. Selective COX-2 inhibitors: pharmacology, clinical effects and therapeutic potential. London: William Harvey Press, 1997: 127-33.
31. Lipsky PE, Isakson PC Outcome of specific COX-2 inhibition in rheumatoid arthritis. J Rheumatol. 24:1997;9-14.
32. Mengle-Gaw L, Hubbard RC, Karim A, et al. A study of the platelet effects of SC-58635, a novel COX-2-selective inhibitor. Arthritis Rheum 1997; 40 (suppl 9): S93.
33. Celebrex data sheet. Searle, 1999.
34. Hubbard RC, Mehlisch DR, ANOTHER NAME, et al. SC-58635, a highly selective inhibitor of COX-2, is an effective analgesic in an acute post surgical pain model. J Invest Med 1996; 44: 293A.
35. Mehlisch DR, Hubbard RCet al. Analgesic efficacy and plasma levels of a highly selective inhibitor of COX-2 (SC-58635; SC) in patients with post-surgical dental pain. Clin Pharmacol Ther. 61:1997;195.
36. Simon LS, Lanza FLet al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor. Arthritis Rheum. 41:1998;1591-1602.
37. Hubbard RC, Geiss GS, Woods EM, Yu JS, Zhao W. Efficacy, tolerability, and safety of celecoxib, a specific COX-2 inhibitor, in osteoarthritis. Rheumatol Eur 1998; 27 (suppl 1): 118.
38. Geiss GS, Hubbard RC, Callison DA, Yu S, Zhao W. Safety and efficacy of celecoxib, a specific COX-2 inhibitor. Rheumatol Eur 1998; 27 (suppl 1): 118.
39. Geiss GS, Stead H, Morant SV, Nandin R, Hubbard RC. Endoscopic and tolerability, results from a study of celecoxib, a specific COX-2 inhibitor, in patients with rheumatoid arthritis. Rheumatol Eur 1998; 27 (suppl 1): 118.
40. Zhao SZ, Hatoum HT, Hubbard ACet al. Effect of celecoxib, a novel COX-2 inhibitor, on health-related quality of life of patients with osteoarthritis of the knee. Arthritis Rheum. 40:1997;S88.
41. Lanza FL, Rack MF, Callison DA, et al. A pilot endoscopic study of the gastroduodenal effects of SC-58635, a novel COX-2-selective inhibitor. Gastroenterology 1997; 112 (suppl 4): A194.
42. Ehrich EW, Dallob A, De Lepeleire I, et al. Inhibition of the cyclooxygenase-2 isoform by rofecoxib is sufficient for analgesic efficacy in the dental pain model Clin Pharm Ther (in press).
43. Depre M, Ehrich E, DeLepeleire I, et al. Demonstration of specific COX-2 inhibition by MK966 (Vioxx) in humans with supratherapeutic doses. Rheumatol Eur 1998; 27 (suppl 1).
44. Ehrich E, Mehlisch D, Perkins S, et al. Efficacy of MK-966, a highly selective inhibitor of COX-2, in the treatment of postoperative dental pain. Arthritis Rheum 1996; 39 (suppl 9): S81.
45. Mehlisch DR, Mills S, Sandler Met al. Ex vivo assay of COX-2 inhibition predicts analgesic efficacy in post-surgical dental pain with MK-966. Clin Pharmacol Ther. 63:1998;139.
46. Schwartz J, Mukhopadhyay S, McBride Ket al. Antipyretic activity of a selective cyclooxygenase (COX)-2 inhibitor, MK-0966. Clin Pharmacol Ther. 63:1998;167.
47. Ehrich E, Schnitzer T, Kivitz A, et al. MK-966, a highly selective COX-2 inhibitor, was effective in the treatment of osteoarthritis (OA) of the knee and hip in a six-week placebo controlled study. Arthritis Rheum 1997; 40 (suppl 9): S85.
48. Saag K, Fisher C, McKay J, et al. MK-0966, a specific COX-2 inhibitor, has clinical efficacy comparable to ibuprofen in the treatment of knee and hip osteoarthritis (OA) in a six-week controlled clinical trial. Arthritis Rheum 1998; 41 (suppl 9): S84.
49. Cannon G, Caldwell J, Holt P, et al. MK-0966, a specific COX-2 inhibitor, has clinical efficacy comparable to diclofenac in the treatment of knee and hip osteoarthritis (OA) in a 26-week controlled clinical trial. Arthritis Rheum 1998; 41 (suppl 9): S83.
50. Ehrich E, Bolognese J, Watson DJ, et al. The effect of MK-0966 (Vioxx), a COX-2 specific inhibitor on the health-related quality of life in osteoarthritis patients. EULAR.
51. Lanza F, Simon T, Quan Het al. Selective inhibition of cyclooxygenase-2 (COX-2) with MK-0966 (250 mg qd) is associated with less gastroduodenal damage than aspirin (ASA) 650 mg qid or ibuprofen (IBU) 800 mg tid. Gastroenterology. 112:1997;A194.
52. Cryer B, Gottesdiener MD, Gertz B, Hsieh P, Dallob A, Feldman M Effects of a novel cyclooxygenase (COX)-2 inhibitor on gastric mucosal prostaglandin (PG) synthesis in healthy humans. Am J Gastroenterol. 93:1998;A104.
53. Hunt R, Bowen B, James Cet al. COX-2 specific inhibition with MK-0966 or 50 mg qd over 4 weeks does not increase fecal blood loss: a controlled study with placebo and ibuprofen 800 mg tid. Am J Gastroenterol. 93:1998;A247.
54. Bjarnason I, Sigthorssen G, Crane Ret al. COX-2 specific inhibition with MK-0966 25 or 50 mg qd does not increase intestinal permeability: a controlled study with placebo and indomethacin 50 mg tid. Am J Gastroenterol. 93:1998;A246.
55. Smolen J. Clinical trials of COX-2 inhibitors. In: Vane J, ed. The promise of specific COX-2 inhibition by novel agents. London: William Harvey Press 1998: 21.
56. Chan CC, Boyce S, Brideau C, et al. A new class of potent, orally active and selective COX-2 inhibitor-preclinical pharmacology. Inflamm Res 1997; 46 (suppl 3): S242.
57. Donnelly MT, Hawkey CJ Review article: COX-II inhibitors - a new generation of safer NSAIDs? Aliment Pharmacol Ther. 11:1997;227-236.
58. Kawamori T, Rao CV Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res. 58:1998;409-412.
59. Pasinette GM, Aisen PS. Cyclooxygenase 2 expression is increased in frontal cortex of Alzheimer's disease brain. Neuroscience (in press).
60. McGeer PL, Schulzer M, McGeer EG Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology. 47:1996;425-432.
61. McLaughlan J, Seth R, Cole AT, Scott BB, Jenkins D, Hawkey CJ Increased inducible cyclooxygenase associated with treatment failure in ulcerative colitis. Gastroenterrology. 110:1996;A964.
62. Mizuno H, Sakamoto C, Matsuda K Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology. 112:1997;387-397.
63. Schmassmann A, Peskar BM, Stettler Cet al. Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastro-intestinal ulcer models in rats. Br J Pharmacol. 123:1998;795-804.
64. Hawkey CJ, Jeffrey AK, Szczepanski Let al. A comparison of omeprazole and misoprostol for treating and preventing ulcers associated with non-steroidal anti-inflammatory drugs. N Engl J Med. 338:1998;727-734.
65. Yeomans ND, Tulassay Z, Juhasz Let al. A comparison of omeprazole and ranitidine for treating and preventing ulcers associated with non-steroidal anti-inflammatory drugs. N Engl J Med. 338:1998;719-726.
66. Harris RC, McKanna JA, Akai Y, Jacobson HR, Dubois RN, Breyer MD Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest. 94:1994;2504-2510.
67. Crankshaw, DJ, Dyal R. Effects of some naturally occurring prostanoids and some cyclooxygenase inhibitors on the contraction of the human uterine segment in vivo. Can J Physiol Pharmacol 1994; 870-74.
68. Schmedtje JF Jr., Ji YS, Liu WL, DuBois RN, Runge MJ Hypoxia induces cyclooxygenase-2 via the NF-KappaB pbs transcription facts in human vascular endothelial cells. J Biol Chem. 272:1997;601-608.
69. Wallace JL, Bak A, McKnight W, Asfaha S, Sharka KA, MacNaughton WK Cyclooxygenase-1 contributes to inflammatory responses in rats and mice: implications for gastrointestinal toxicity. Gastroenterology. 115:1998;101-109.
70. Mahler JF, Davis BJ, Morham SG, Lanenbach R Disruption of cyclooxygenase genes in mice. Toxicol Pathol. 24:1997;717-719.
71. Donnelly MT, Stack WA, Courtauld EM, Garlick N, Del Soldato P, Hawkey CJ Nitric oxide donating flurbiprofen (HCT 1026) causes less endoscopic damage in healthy volunteers than flurbiprofen. Gastroenterology. 114:1998;A107.
72. Hawkey CJ Future treatments for arthritis - new NSAIDs. NO-NSAIDs or no NSAIDs? Gastroenterology. 109:1995;614-616.
73. Elliott SN, McKnight W, Cirino G, Wallace JL A nitirc oxide-releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in rats. Gastroenterology. 109:1995;524-530.
74. Stack WA, Hawkey GM, Atherton JCet al. NSAIDs and CagA positive H pylori but not CagA negative H pylori as independent risk factors for bleeding peptic ulcers. Gastroenterology. 114:1998;A294.
75. Silverstein FE, Graham DY, Senior JRet al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 123:1995;241-249.